NovaBridge Biosciences (NBP) Cash from Discontinued Operations (2020 - 2024)
NovaBridge Biosciences (NBP) reported Cash from Discontinued Operations of 61862000.0 for Q4 2024, up 133.79% quarter-over-quarter from 26460000.0 in Q3 2024.
NovaBridge Biosciences (NBP) Cash from Discontinued Operations (2020 - 2024) Analysis & Trends
NovaBridge Biosciences (NBP) has 2 years of Cash from Discontinued Operations data on file, last reported at 61862000.0 in Q4 2024.
- Cash from Discontinued Operations for Q4 2024 came in at 61862000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 88322000.0 (down 0.81% YoY), and the FY2024 annual result was 34364000.0, up 131.3% from the prior year.
- Cash from Discontinued Operations improved to 61862000.0 in Q4 2024 per NBP's latest filing, from 26460000.0 in the prior quarter.
- Over five years, Cash from Discontinued Operations peaked at 61862000.0 in Q4 2024 and troughed at 33640206.31 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discont. Ops (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 2 | Belite Bio | 55,234.00 Bn | 55,234.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,823.14 Bn | 17,823.14 Bn | - | - |
| 4 | Legend Biotech | 3,624.50 Bn | 3,624.21 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,745.73 Bn | 1,745.73 Bn | - | - |
| 6 | Evaxion A | 1,540.85 Bn | 1,540.84 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.57 Bn | 105.33 Bn | 2.59 Bn | - |
| 9 | Abivax | 93.46 Bn | 93.46 Bn | - | -59.14 Mn |
| 10 | NovaBridge Biosciences | 331.49 Mn | 120.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 61.86 Mn |
| Dec 31, 2024 | 61.86 Mn |
| Sep 30, 2024 | 26.46 Mn |
| Sep 30, 2024 | 26.46 Mn |
| Jun 30, 2024 | 34.36 Mn |
| Jun 30, 2024 | 34.36 Mn |
| Sep 30, 2020 | -33.64 Mn |
| Sep 30, 2020 | -33.64 Mn |